Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19


Posted: 2021-09-15 19:00:00
. 2021 Sep 3;S0264-410X(21)01165-8. doi: 10.1016/j.vaccine.2021.08.103. Online ahead of print. Zehua Zhou 1 , Xinyu Zhang 2 , Qianqian Li 3 , Lili Fu 3 , Meiyu Wang 3 , Shuo Liu 3 , Jiajing Wu 3 , Jianhui Nie 3 , Li Zhang 3 , Chenyan Zhao 3 , Fei Jiang 3 , Yimeng An 3 , Bin Yu 4 , Haifa Zheng 5 , Youchun Wang 6 , Aihua Zhao 7 , Weijin Huang 8 Affiliations Expand Affiliations 1 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; Beijing Minhai Biotechnology Co., Ltd, China. 2 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; College of Life Science, Jilin University, Changchun, China. 3 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. 4 College of Life Science, Jilin University, Changchun, China. 5 Beijing Minhai Biotechnology Co., Ltd, China. 6 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: wangyc@nifdc.org.cn. 7 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: tbtestlab@nifdc.org.cn. 8 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: huangweijin@nifdc.org.cn. Item in Clipboard Zehua Zhou et al. Vaccine. 2021. Show details Display options Display options Format . 2021 Sep 3;S0264-410X(21)01165-8. doi: 10.1016/j.vaccine.2021.08.103. Online ahead of print. Authors Zehua Zhou 1 , Xinyu Zhang 2 , Qianqian Li 3 , Lili Fu 3 , Meiyu Wang 3 , Shuo Liu 3 , Jiajing Wu 3 , Jianhui Nie 3 , Li Zhang 3 , Chenyan Zhao 3 , Fei Jiang 3 , Yimeng An 3 , Bin Yu 4 , Haifa Zheng 5 , Youchun Wang 6 , Aihua Zhao 7 , Weijin Huang 8 Affiliations 1 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; Beijing Minhai Biotechnology Co., Ltd, China. 2 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China; College of Life Science, Jilin University, Changchun, China. 3 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. 4 College of Life Science, Jilin University, Changchun, China. 5 Beijing Minhai Biotechnology Co., Ltd, China. 6 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: wangyc@nifdc.org.cn. 7 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: tbtestlab@nifdc.org.cn. 8 Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and WHO Collaborating Center for Standardization and Evaluation of Biologicals, No.31 Huatuo Street, Daxing District, Beijing 102629, China. Electronic address: huangweijin@nifdc.org.cn. Item in Clipboard CiteDisplay options Display options Format Abstract The development of an effective vaccine to control the global coronavirus disease-2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus- 2 (SARS-CoV-2) is of utmost importance. In this study, a synthetic DNA-based vaccine candidate, known as pSV10-SARS-CoV-2, expressing the SARS-CoV-2 spike protein was designed and tested in 39 BALB/c mice with BC01, an adjuvant derived from unmethylated CpG motif-containing DNA fragments from the Bacillus Calmette-Guerin genome. Mice vaccinated with pSV10-SARS-CoV-2 with BC01 produced early neutralizing antibodies and developed stronger humoral and cellular immune responses compared to mice that received the DNA vaccine only. Moreover, sera from mice vaccinated with pSV10-SARS-CoV-2 with BC01 can neutralize certain variants, including 614G, 614G + 472 V, 452R, 483A, 501Y.V2, and B.1.1.7. The results of this study demonstrate that the addition of BC01 to a DNA-vaccine for COVID-19 could elicit more effective neutralizing antibody titers for disease prevention. Keywords: BC01 adjuvant; COVID-19; DNA vaccine; SARS-COV-2. Copyright © 2021. Published by Elsevier Ltd. Conflict of interest statement Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. [x] Cite Copy Format: Send To [x]

参考サイト PubMed: covid-19


Powered by Kreditvergleich


バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
7月 18, 2021 バイオアソシエイツ

COVID-19モノクローナル抗体療法は、高リスク患者に早期投与することで医療システムの負担を軽減することができるとの報告

南フロリダ大学(USF Health)とタンパ総合病院(Tampa General Hospital)が新たに発表した研究によると、モノクローナル抗体は、リスクの高い患者に早期に投与することで、 COVID-19 に関連する救急外来の受診や入院を減少させる効果があることがわかった。FDAのガイドラインに沿って使用すれば、この治療法は、パンデミックによる患者や限られた医療資源への継続的な負担を軽減することができる、と研究者らは提案している。この共同研究は、2021年6月4日にOpen Forum…